Lexeo Therapeutics, Inc. (LXEO)
Data as of , from SEC Form 4 filings.
See up to 3 months of LXEO. The 7-day demo opens the 1M and 3M ranges and puts LXEO on your watchlist.
Start 7-day demoLatest LXEO insider trades
- Louis Edward Tamayo - OfficerOpen-market sale$20K
Richard Nolan Townsend - OfficerOpen-market sale
About Lexeo Therapeutics, Inc. (LXEO)
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.
- NEW YORK, NY
- 59
- 2023
- XNAS
LXEO Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 3 | 8,766 | $43K |
| Grant or award | 7 | 316,880 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
LXEO insider transactions (Form 4)
4153 Form 4 filings on record, the earliest from Oct 15, 2024, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Louis Edward Tamayo - Officer | Grant or award | Stock Option (right to buy) | 54,750 | $0.00 | - | |
 Narinder Pal Bhalla - Officer | Grant or award | Common Stock | 2,714 footnote F1 | $3.58 | $10K | |
| Narinder Pal Bhalla - Officer | Grant or award | Stock Option (right to buy) | 54,750 | $0.00 | - | |
| ||||||
| Jose Manuel Otero - Officer | Grant or award | Common Stock | 2,110 footnote F1 | $2.64 | $6K | |
| Jose Manuel Otero - Officer | Grant or award | Stock Option (right to buy) | 54,750 | $0.00 | - | |
| ||||||
| Richard Nolan Townsend - Officer | Grant or award | Common Stock | 2,306 footnote F1 | $2.64 | $6K | |
| Richard Nolan Townsend - Officer | Grant or award | Stock Option (right to buy) | 145,500 | $0.00 | - | |
| ||||||
| Louis Edward Tamayo - Officer | Open-market sale | Common Stock | 4,117 | $4.91 footnote F2 | $20K | |
| ||||||
| Richard Nolan Townsend - Officer | Open-market sale | Common Stock | 3,345 | $4.95 footnote F2 | $17K | |
| ||||||
| Jose Manuel Otero - Officer | Open-market sale | Common Stock | 1,304 | $4.96 footnote F2 | $6K | |
| ||||||
| Louis Edward Tamayo - Officer | Grant or award | Common Stock | 12,000 | $0.00 | - | |
| Louis Edward Tamayo - Officer | Open-market sale | Common Stock | 4,641 | $4.49 footnote F2 | $21K | |
| ||||||
| Jose Manuel Otero - Officer | Grant or award | Common Stock | 12,060 | $0.00 | - | |
| Jose Manuel Otero - Officer | Open-market sale | Common Stock | 4,666 | $4.48 footnote F2 | $21K | |
| ||||||
| Narinder Pal Bhalla - Officer | Grant or award | Common Stock | 55,000 | $0.00 | - | |
| Narinder Pal Bhalla - Officer | Open-market sale | Common Stock | 22,306 | $4.42 footnote F2 | $99K | |
| ||||||
| Richard Nolan Townsend - Officer | Grant or award | Common Stock | 67,000 | $0.00 | - | |
| Richard Nolan Townsend - Officer | Open-market sale | Common Stock | 25,947 | $4.48 footnote F2 | $116K | |
| ||||||
| Steven Altschuler | Grant or award | Stock Option (right to buy) | 35,000 | $0.00 | - | |
 Mette Kirstine Agger | Grant or award | Stock Option (right to buy) | 35,000 | $0.00 | - | |
 Brenda Cooperstone | Grant or award | Stock Option (right to buy) | 35,000 | $0.00 | - | |
| Reinaldo M. Diaz | Grant or award | Stock Option (right to buy) | 35,000 | $0.00 | - | |
| Tolga Tanguler | Grant or award | Stock Option (right to buy) | 35,000 | $0.00 | - | |
| Hauwermeiren Timothy van | Grant or award | Stock Option (right to buy) | 35,000 | $0.00 | - | |
| Paula H. Cholmondeley | Grant or award | Stock Option (right to buy) | 35,000 | $0.00 | - | |
| Jose Manuel Otero - Officer | Open-market sale | Common Stock | 1,302 | $5.07 footnote F2 | $7K | |
| ||||||
| Richard Nolan Townsend - Officer | Open-market sale | Common Stock | 3,342 | $5.06 footnote F2 | $17K | |
| ||||||
| Richard Nolan Townsend - Officer | Open-market sale | Common Stock | 55,000 | $5.69 footnote F2 | $313K | |
| ||||||
| Richard Nolan Townsend - Officer | Grant or award | Common Stock | 2,623 footnote F1 | $2.64 | $7K | |
| ||||||
| Jose Manuel Otero - Officer | Grant or award | Common Stock | 5,930 footnote F1 | $2.64 | $16K | |
| ||||||
| Jose Manuel Otero - Officer | Open-market sale | Common Stock | 3,016 | $6.40 footnote F2 | $19K | |
| ||||||
| Richard Nolan Townsend - Officer | Open-market sale | Common Stock | 10,173 | $6.38 footnote F2 | $65K | |
| ||||||
| Narinder Pal Bhalla - Officer | Grant or award | Common Stock | 49,500 footnote F1 | $0.00 | - | |
| Narinder Pal Bhalla - Officer | Grant or award | Stock Option (right to buy) | 297,000 | $0.00 | - | |
| ||||||
| Richard Nolan Townsend - Officer | Grant or award | Common Stock | 161,665 footnote F1 | $0.00 | - | |
| Richard Nolan Townsend - Officer | Grant or award | Stock Option (right to buy) | 646,665 | $0.00 | - | |
| ||||||
| Jose Manuel Otero - Officer | Grant or award | Common Stock | 65,000 footnote F1 | $0.00 | - | |
| Jose Manuel Otero - Officer | Grant or award | Stock Option (right to buy) | 260,000 | $0.00 | - | |
| ||||||
| Louis Edward Tamayo - Officer | Grant or award | Common Stock | 44,665 footnote F1 | $0.00 | - | |
| Louis Edward Tamayo - Officer | Grant or award | Stock Option (right to buy) | 226,665 | $0.00 | - | |
| ||||||
| Jose Manuel Otero - Officer | Open-market sale | Common Stock | 721 | $9.27 footnote F2 | $7K | |
| ||||||
Item 2.01, 3.02, 9.01
Item 1.01, 8.01, 9.01
Item 2.02, 8.01, 9.01
Item 5.07
Recent LXEO Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Otero Jose Manuel | Officer | 1,304 | $6K | View on EDGAR | |
| Townsend Richard Nolan | Officer, Director | 3,345 |
LXEO insider trading FAQ
What is the latest insider trade for LXEO?
Lexeo Therapeutics, Inc. (LXEO) had 7 insider filings in the last 90 days, with the most recent on 2026-09-28. The full record for LXEO runs to 53 Form 4 filings, the earliest from 2024-10-15. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying LXEO stock?
No insider purchases of LXEO were filed in the last 90 days. 1 purchase is on record for this company.
How many insiders are selling LXEO stock?
3 insider sales of LXEO were filed in the last 90 days, totaling $43K.
Where can I see LXEO SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects LXEO Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Louis Edward Tamayo view on EDGAR
- - Narinder Pal Bhalla view on EDGAR
- - Jose Manuel Otero view on EDGAR
- - Richard Nolan Townsend view on EDGAR
- - Louis Edward Tamayo view on EDGAR
- - Richard Nolan Townsend view on EDGAR
- - Jose Manuel Otero view on EDGAR
- - Louis Edward Tamayo view on EDGAR
- - Jose Manuel Otero view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where LXEO's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow LXEO with a 7-day demo
- LXEO on your watchlist
- Every LXEO Form 4 filing on record
- Up to 3 months of LXEO price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
